Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices.
Nick BansbackJeffrey R CurtisJie HuangZeling HeMichael EvansTracy JohanssonKaleb D MichaudGabriela SchmajukKatherine P LiaoPublished in: ACR open rheumatology (2020)
The uptake of biosimilars in the United States remains low despite persistence on infliximab-dyyb being similar to the infliximab bio-originator. These results add to clinical studies that should provide greater confidence to patients and physicians regarding biosimilar use.